AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04123340 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Additional intraprocedural pre-ablation CT-scan
Description: In 20 patients, besides de regular post-RFA scan, a pre-RFA contrast enhanced dual phase CT-scan will be acquired to investigate the feasibility of quantitative ablation assessment.
Study NCT02243306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: Round, biconvex, white film coated tablet containing 5 mg GSK1278863.
Study NCT01888965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: All patients in the study will receive Dovitinib, 500 mg orally daily for 5 days followed by 2 days off (7 day cycles) for up to 2 years.~If 500 mg is intolerable, 400 mg will be dosed. If 400 mg is intolerable, 300 mg will be dosed
Study NCT04143256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL ENDS 5% Virginia Tobacco
Description: JUUL ENDS Virginia Tobacco 5% nicotine strength
Study NCT04143256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL 3% Virginia Tobacco ENDS
Description: JUUL ENDS Virginia Tobacco 3% nicotine strength
Study NCT04143256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL 5% Mint ENDS
Description: JUUL ENDS Mint 5% nicotine strength
Study NCT04143256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL 3% Mint ENDS
Description: JUUL ENDS Mint 3% nicotine strength
Study NCT04143256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL 5% Menthol ENDS
Description: JUUL ENDS Menthol 5% nicotine strength
Study NCT04143256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL 3% Menthol ENDS
Description: JUUL ENDS Menthol 3% nicotine strength
Study NCT04143256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL 5% Mango ENDS
Description: JUUL ENDS Mango 5% nicotine strength
Study NCT04143256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL 3% Mango ENDS
Description: JUUL ENDS Mango 3% nicotine strength
Study NCT04143256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: US Cigarette, Non-menthol - Marlboro Gold King Size
Description: US Cigarette, Non-menthol - Marlboro Gold King Size
Study NCT04143256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: US Cigarette, Menthol - Newport King Size
Description: US Cigarette, Menthol - Newport King Size
Study NCT02668679 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sedation of children during gastroscopy with and without the presence of dream doctor
Description: children and their parents with and without the presence of DD upon arrival to the Gastroenterology institute and throughout the induction of sedation, gastroscopy and recovery.
Study NCT02668679 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sedation of children during gastroscopy with and without the presence of dream doctor
Description: children and their parents with and without the presence of DD upon arrival to the Gastroenterology institute and throughout the induction of sedation, gastroscopy and recovery.
Study NCT02668679 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: evaluation of stress with PPI and GSR
Description: evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of PPI and GSR
Study NCT02668679 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: evaluation of stress with PPI and GSR
Description: evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of PPI and GSR
Study NCT02668679 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood specimens for stress hormones
Description: evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of stress hormones.
Study NCT02668679 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: blood specimens for stress hormones
Description: evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of stress hormones.
Study NCT02668679 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiological indices for evaluation of stress
Description: evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of blood pressure, pulse, saturation and body temperature.
Study NCT02668679 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiological indices for evaluation of stress
Description: evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of blood pressure, pulse, saturation and body temperature.
Study NCT03523403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apples
Description: 3 whole Ontario-grown Gala apples
Study NCT03996655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Injection [Bridion]
Description: Reversal of neuromuscular blockers
Study NCT03996655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Reversal of neuromuscular blockers
Study NCT00914095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylphenidate
Description: 10 mg tablet of methylphenidate 3 times a day (1 mg/kg/day)
Study NCT00914095 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablets of placebo 3 times a day
Study NCT04340089 — intervention group
Intervention type: BEHAVIORAL
Intervention: squatting on the toilet
Description: the patients could go to squatting on the toilet at any time as they want to after taking the capsule
Study NCT01666392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid
Description: Omega-3 fatty acid, Eicosapentaenoic acid+docosahexaenoic acid in capsule form
Study NCT00083616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab 6 mg/kg every once 2 weeks weeks administered by intravenous (IV) infusion.
Study NCT00738322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: Solution for iv infusion, single dose
Study NCT00738322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl solution for iv infusion, single dose
Study NCT03894501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Oriented Recovery Enhancement
Description: MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
Study NCT03894501 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Methadone program behavioral treatment as usual
Description: In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
Study NCT01256957 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HEPA filter
Study NCT01666392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00551668 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: proximal patellar surgery
Description: Initial proximal patellar surgery
Study NCT00551668 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonoperative
Description: Nonoperative without surgery
Study NCT02268578 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: 2mA tDCS
Study NCT02268578 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: Transcranial Direct Current Stimulation is administered but at 0mA
Study NCT00555152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00555152 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02821377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous furosemide
Description: treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) plus small volumes of HSS (150mL 1.4-4.6% NaCl), from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.
Study NCT02821377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline solutions
Description: Intravenous small volumes of HSS (150mL 1.4-4.6% NaCl), plus treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.
Study NCT02821377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Seriated paracentesis
Description: repeated paracentesis from the first day after admission until 3 days before discharge
Study NCT02947165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIS793
Description: Anti-TGF beta antibody tested on a Q3W regimen or alternative Q2W regimen.
Study NCT02947165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Anti-PD-1 antibody tested on a Q3W regimen or alternative Q4W regimen.
Study NCT01794741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dymista Nasal Spray
Study NCT01794741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate nasal spray
Study NCT03797118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFR
Description: Fractional flow reserve measured during cardiac catheterization
Study NCT03117608 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: injection of autologous micro-fragmented adipose tissue (aMAT)
Description: adipose tissue will be obtained from abdominal region or buttocks and aMAT, and processed with Lipogems® technology.
Study NCT03117608 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: injection of Platelet-rich Plasma (PRP)
Description: injection of platelet-rich plasma
Study NCT01156389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir and Pyramax
Description: 100 mg ritonavir (one soft gelatin capsule twice per day over 17 days, the evening capsule on day 1 will be omitted) and Pyramax (pyronaridine/artesunate) 180:60 mg (3 to 4 tablets once per day according to weight for 3 days).
Study NCT01156389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyramax
Description: Pyramax (pyronaridine/artesunate) 180:60 mg (3 to 4 tablets once per day according to weight for 3 days).
Study NCT01524432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-fungal agent (Clotrimazole) loaded microcapsules
Description: Clotrimazole loaded microcapsules padded on socks and the patient should wear the socks every day for 2 weeks
Study NCT01524432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No drug loaded microcapsules socks
Study NCT00118352 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Given IV
Study NCT00118352 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo low-dose TBI
Study NCT00118352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT06095349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inhalatory treatment with sulfureous aerosol
Description: osteopenic patients are subject to a 12-days cycle of 30 minutes-long inhalatory treatment with sulfureous aerosol
Study NCT03110757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-AF
Description: Previously referred to as Gluco-pyranosylphospho-lipid A aqueous formulation (GLA-AF). It is a toll-like receptor-4 agonist
Study NCT00555152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib Ditosylate
Description: Given PO
Study NCT00555152 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT03203681 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Natesto
Description: 4.5% nasal testosterone. 11.0 mg testosterone administered per dose (2 pump actuations, 1 pump per nostril) applied intranasally three times a day.
Study NCT04419012 — intervention group
Intervention type: OTHER
Intervention: observation
Description: observation
Study NCT02125721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiopronin 1g per day
Description: 500mg PO BID x 7 days
Study NCT02125721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiopronin 2g per day
Description: 1g PO BID x 7 days
Study NCT02125721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiopronin 3g per day
Description: 1.5g PO BID x 7 days
Study NCT00812448 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tea catechin extracts
Description: catechins are composed of tea catechin extracts available in grren tea supplements
Study NCT04028596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: once, 1000mg, 2 h before ECT session
Study NCT04204057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenalisib
Description: Tenalisib 800 mg BID, Orally
Study NCT05395286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Innovation Lab
Description: An Innovation Lab is a facilitated 5-day residential event designed to create novel, transdisciplinary and potentially transformative research ideas and proposals to address a specific grand challenge. Participants, along with a director, organizers, subject matter guides, and KI facilitators communally explore the problem space, generate a broad range of ideas, and form transdisciplinary teams to pursue research projects.
Study NCT00118352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given PO or IV
Study NCT00118352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO
Study NCT00118352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic stem cell transplantation
Study NCT00118352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo PBSCT
Study NCT00118352 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: graft versus host disease prophylaxis/therapy
Description: Undergo GVHD prophylaxis/therapy
Study NCT00118352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02049190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onapristone
Study NCT02049190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone
Study NCT02699008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Antiplatelet agent
Study NCT02699008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: New P2Y12 receptor inhibitor antiplatelet agent
Study NCT02632201 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIK-HER2
Description: DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PIK-HER2 cell suspension (1-6×109 PIK-HER2 + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
Study NCT02632201 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC-PMAT
Description: DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
Study NCT01703117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: 20-22 subjects between the ages of 60-85 will receive study drug.
Study NCT01703117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20-22 subjects between the ages of 60-85 will receive placebo
Study NCT03469830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SSCP
Description: Insert
Study NCT03469830 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SPMS
Description: Pressure therapy
Study NCT04028596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimotop
Description: once, 60mg, 2 h before ECT session
Study NCT01103284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DiaPep277
Description: 1.0 mg dose in 0.5 mL of solution
Study NCT01103284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40 mg mannitol in 0.5 mL of solution.~Dosing: 0, 1, 3, 6, 9, 12, 15, 18, 21, 24 months
Study NCT02493608 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: scalpel
Description: used to cut the abdominal wall.
Study NCT02493608 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diathermy
Description: Diathermy used to cut , coagulate the tissue
Study NCT02461355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aphasia therapy
Description: Aphasia therapy using a computerized scripting program
Study NCT02461355 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Aphasia therapy
Description: Aphasia therapy using a computerized scripting program
Study NCT02461355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: Anodal transcranial direct current stimulation using the Chattanooga Ionto device
Study NCT02461355 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham transcranial direct current stimulation using the Chattanooga Ionto device
Study NCT01953341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 333
Description: Oral administration available in varying dose strength.
Study NCT01953341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo containing no active drug
Study NCT03345667 — intervention group
Intervention type: DRUG
Intervention: lucentis
Description: Use of lucentis and other anti-vegf in patients with diabetic retinopathy
Study NCT01194479 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Formoterol
Description: Formoterol inhaler, 12mcg capsules, 4 capsules for one administration
Study NCT01194479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Formoterol inhaler, 12mcg capsules, 4 capsules for one administration
Study NCT01194479 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Participants in both arms received placebo on 1 of the 2 visits.
Study NCT01194479 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants in both arms received placebo on 1 of the 2 visits.
Study NCT02085785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coached group
Description: Participants randomized to the coached arm will receive 1) education and self-monitoring materials \[e.g., a booklet, calorie count book, pedometer, and scale (if they do not have one)\], 2) a home visit by an exercise specialist, and 3) 11 telephone calls (over a 20-week period) by a health coach who will utilize motivational interviewing techniques to help the participant set eating and activity goals and trouble shoot problems when they occur
Study NCT02085785 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-directed control group
Description: Participants randomized to the self-directed control arm will receive the same educational and self-monitoring materials as the coached group \[e.g., a booklet, calorie count book, pedometer, and scale (if they do not have one)\], but no home visit and no coaching calls. They will be encouraged to make behavior changes on their own.